CO6751242A2 - Combinación y composición para el tratamiento de obesidad - Google Patents
Combinación y composición para el tratamiento de obesidadInfo
- Publication number
- CO6751242A2 CO6751242A2 CO13153451A CO13153451A CO6751242A2 CO 6751242 A2 CO6751242 A2 CO 6751242A2 CO 13153451 A CO13153451 A CO 13153451A CO 13153451 A CO13153451 A CO 13153451A CO 6751242 A2 CO6751242 A2 CO 6751242A2
- Authority
- CO
- Colombia
- Prior art keywords
- combination
- obesity
- treatment
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 abstract 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 abstract 1
- 229940086609 Lipase inhibitor Drugs 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005802 health problem Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000280 phytoalexin Substances 0.000 abstract 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
- C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención tiene su aplicación en el campo farmacéutico, especialmente en el de combinación y composiciones farmacéuticas que comprenden un inhibidor de la lipasa y una fitoalexina y vehículos o excipientes farmacéuticamente aceptables; la presente invención también se relaciona con el proceso de fabricación de composiciones que contienen la combinación y el uso de dicha composición en el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados..
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010014484A MX336980B (es) | 2010-12-21 | 2010-12-21 | Combinacion y composicion para el tratamiento de obesidad. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6751242A2 true CO6751242A2 (es) | 2013-09-16 |
Family
ID=46313244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13153451A CO6751242A2 (es) | 2010-12-21 | 2013-06-28 | Combinación y composición para el tratamiento de obesidad |
Country Status (15)
Country | Link |
---|---|
US (1) | US9433602B2 (es) |
AR (1) | AR084435A1 (es) |
BR (1) | BR112013015489A2 (es) |
CA (1) | CA2822213C (es) |
CL (1) | CL2013001731A1 (es) |
CO (1) | CO6751242A2 (es) |
CR (1) | CR20130298A (es) |
DO (1) | DOP2013000144A (es) |
ES (1) | ES2422877B1 (es) |
GB (1) | GB2500357B (es) |
GT (1) | GT201300169A (es) |
MX (1) | MX336980B (es) |
PE (1) | PE20140697A1 (es) |
RU (1) | RU2608928C2 (es) |
WO (1) | WO2012085785A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10743813B2 (en) | 2014-09-11 | 2020-08-18 | Rattan Nath | Diabetes control using postprandial feedback |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539361A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
GB9914744D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
EP1457206A1 (en) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
EP1838273A4 (en) * | 2005-01-10 | 2013-02-20 | Elc Man Llc | DISCONTINUOUS SURFACE COATING FOR PARTICLES |
CN103055313A (zh) * | 2005-07-07 | 2013-04-24 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
US7771632B2 (en) * | 2006-05-15 | 2010-08-10 | American Leistritz Extruder Corp. | Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets |
BRPI0817053A2 (pt) * | 2007-09-17 | 2015-03-24 | Reddys Lab Ltd Dr | Formulações farmacêuticas de orlistat |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
-
2010
- 2010-12-21 MX MX2010014484A patent/MX336980B/es active IP Right Grant
-
2011
- 2011-12-16 ES ES201390069A patent/ES2422877B1/es active Active
- 2011-12-16 US US13/996,410 patent/US9433602B2/en active Active
- 2011-12-16 CA CA2822213A patent/CA2822213C/en active Active
- 2011-12-16 WO PCT/IB2011/055723 patent/WO2012085785A1/es active Application Filing
- 2011-12-16 PE PE2013001445A patent/PE20140697A1/es active IP Right Grant
- 2011-12-16 GB GB1312583.6A patent/GB2500357B/en not_active Expired - Fee Related
- 2011-12-16 BR BR112013015489-6A patent/BR112013015489A2/pt not_active Application Discontinuation
- 2011-12-16 RU RU2013127794A patent/RU2608928C2/ru not_active IP Right Cessation
- 2011-12-20 AR ARP110104818A patent/AR084435A1/es unknown
-
2013
- 2013-06-14 CL CL2013001731A patent/CL2013001731A1/es unknown
- 2013-06-19 CR CR20130298A patent/CR20130298A/es unknown
- 2013-06-20 DO DO2013000144A patent/DOP2013000144A/es unknown
- 2013-06-21 GT GT201300169A patent/GT201300169A/es unknown
- 2013-06-28 CO CO13153451A patent/CO6751242A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
GT201300169A (es) | 2014-04-04 |
ES2422877A2 (es) | 2013-09-16 |
MX2010014484A (es) | 2012-06-21 |
ES2422877B1 (es) | 2014-07-17 |
CR20130298A (es) | 2013-07-09 |
AR084435A1 (es) | 2013-05-15 |
ES2422877R1 (es) | 2013-09-26 |
CL2013001731A1 (es) | 2014-01-10 |
RU2608928C2 (ru) | 2017-01-26 |
CA2822213A1 (en) | 2012-06-28 |
PE20140697A1 (es) | 2014-06-25 |
CA2822213C (en) | 2018-06-19 |
RU2013127794A (ru) | 2015-01-27 |
GB2500357A (en) | 2013-09-18 |
US20130316005A1 (en) | 2013-11-28 |
GB2500357B (en) | 2017-09-06 |
WO2012085785A1 (es) | 2012-06-28 |
DOP2013000144A (es) | 2013-10-15 |
BR112013015489A2 (pt) | 2018-05-15 |
US9433602B2 (en) | 2016-09-06 |
MX336980B (es) | 2016-02-09 |
GB201312583D0 (en) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
CL2008001003A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
TN2011000471A1 (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
CL2011000604A1 (es) | Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas. | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
AR082215A1 (es) | Composicion farmaceutica agradable al paladar | |
CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
CL2013000335A1 (es) | Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension. | |
ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
ECSP13012765A (es) | Combinación y composición para el tratamiento de obesidad | |
CO6751242A2 (es) | Combinación y composición para el tratamiento de obesidad | |
CL2008003711A1 (es) | Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica. |